Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648
Tomioka, H.
Archivum Immunologiae et Therapiae Experimentalis 48(3): 183-188
2000
ISSN/ISBN: 0004-069X PMID: 10912623 Document Number: 516917
In this article, I have thoroughly reviewed the status of development of new antimycobacterial drugs, in particular, rifamycin derivatives (rifabutin, rifapentine, and a new benzoxazinorifamycin, KRM-1648), fluoroquinolones (ciprofloxacin, ofloxacin, sparfloxacin, levofloxacin, gatifloxacin, sitafloxacin, moxifloxacin, and others), new macrolides (clarithromycin, azithromycin, roxithromycin), and others. In this review, I have mainly described the in vitro and in vivo activities of these drugs against Mycobacterium tuberculosis and atypical mycobacteria, especially Mycobacterium avium complex. In addition, therapeutic efficacy of these drugs in cases of clinical treatment of mycobacterial infections have also been briefly mentioned.